{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:48:31Z","timestamp":1793155711129,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.intimp.2021.107612","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T03:38:37Z","timestamp":1617421117000},"page":"107612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["A review on applications of abatacept in systemic rheumatic diseases"],"prefix":"10.1016","volume":"96","author":[{"given":"Min","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6273-7997","authenticated-orcid":false,"given":"Shaoxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2021.107612_b0005","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3389\/fimmu.2018.01941","article-title":"T Cell\/B cell collaboration and autoimmunity: an intimate relationship","volume":"9","author":"Petersone","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.107612_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: From mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2021.107612_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101298","article-title":"CTLA-4 (CD152): a versatile receptor for immune-based therapy","volume":"42","author":"Lingel","year":"2019","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imr.12721","article-title":"What did we learn from CTLA-4 insufficiency on the human immune system?","volume":"287","author":"Mitsuiki","year":"2019","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2021.107612_b0025","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/(SICI)1521-4141(199903)29:03<838::AID-IMMU838>3.0.CO;2-P","article-title":"CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells","volume":"29","author":"Fraser","year":"1999","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2006.05.042","article-title":"FOXP3 controls regulatory T cell function through cooperation with NFAT","volume":"126","author":"Wu","year":"2006","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"issue":"6029","key":"10.1016\/j.intimp.2021.107612_b0040","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science (New York, N.Y.)"},{"issue":"5","key":"10.1016\/j.intimp.2021.107612_b0045","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.immuni.2016.05.002","article-title":"Coinhibitory pathways in the B7-CD28 ligand-receptor family","volume":"44","author":"Schildberg","year":"2016","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.intimp.2021.107612_b0050","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/ni1003","article-title":"Modulation of tryptophan catabolism by regulatory T cells","volume":"4","author":"Fallarino","year":"2003","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2021.107612_b0055","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.4049\/jimmunol.172.7.4100","article-title":"Ligation of B7\u20131\/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells","volume":"172","author":"Munn","year":"2004","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"9","key":"10.1016\/j.intimp.2021.107612_b0060","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1084\/jem.189.9.1363","article-title":"Inhibition of T cell proliferation by macrophage tryptophan catabolism","volume":"189","author":"Munn","year":"1999","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.0300-9475.2001.01019.x","article-title":"Expression of CTLA-4 by human monocytes","volume":"55","author":"Wang","year":"2002","journal-title":"Scand. J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107612_b0070","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.humimm.2010.07.007","article-title":"CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions","volume":"71","author":"Laurent","year":"2010","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.intimp.2021.107612_b0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2172-12-21","article-title":"CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation","volume":"12","author":"Wang","year":"2011","journal-title":"BMC Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13317-010-0011-7","article-title":"The soluble CTLA-4 receptor and its role in autoimmune diseases: an update","volume":"1","author":"Saverino","year":"2010","journal-title":"Auto- Immunity Highlights"},{"issue":"5","key":"10.1016\/j.intimp.2021.107612_b0085","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.immuni.2016.04.017","article-title":"Co-stimulatory and co-inhibitory pathways in autoimmunity","volume":"44","author":"Zhang","year":"2016","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2021.107612_b0090","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/rheumatology\/kev403","article-title":"Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis","volume":"55","author":"Bonelli","year":"2016","journal-title":"Rheumatology (Oxford, England)"},{"issue":"20","key":"10.1016\/j.intimp.2021.107612_b0095","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2021.107612_b0100","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.4049\/jimmunol.171.5.2581","article-title":"Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation","volume":"171","author":"Grohmann","year":"2003","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0105","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1527-x","article-title":"Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner","volume":"20","author":"Bozec","year":"2018","journal-title":"Arthritis Res. Therapy"},{"issue":"3","key":"10.1016\/j.intimp.2021.107612_b0110","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1074-7613(01)00191-1","article-title":"OX40 Promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells","volume":"15","author":"Rogers","year":"2001","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.intimp.2021.107612_b0115","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.immuni.2005.03.012","article-title":"Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion","volume":"22","author":"Song","year":"2005","journal-title":"Immunity"},{"issue":"6716","key":"10.1016\/j.intimp.2021.107612_b0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/16717","article-title":"ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28","volume":"397","author":"Hutloff","year":"1999","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.intimp.2021.107612_b0125","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.immuni.2014.12.005","article-title":"The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells","volume":"41","author":"Sage","year":"2014","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0130","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4049\/jimmunol.144.2.532","article-title":"Expression of the human leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens","volume":"144","author":"Tedder","year":"1990","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"6","key":"10.1016\/j.intimp.2021.107612_b0135","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.immuni.2014.12.006","article-title":"Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4","volume":"41","author":"Wing","year":"2014","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2021.107612_b0140","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.4049\/jimmunol.1001311","article-title":"Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells","volume":"185","author":"Platt","year":"2010","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107612_b0145","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.37787","article-title":"Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis","volume":"65","author":"Bonelli","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.intimp.2021.107612_b0150","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.4049\/jimmunol.1302091","article-title":"CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-\u03b3 production in response to mature dendritic cells","volume":"192","author":"Stojanovic","year":"2014","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"4","key":"10.1016\/j.intimp.2021.107612_b0155","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/1744666X.2019.1579642","article-title":"Abatacept for the treatment of rheumatoid arthritis","volume":"15","author":"Pombo-Suarez","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2021.107612_b0160","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/1744666X.2018.1527218","article-title":"Abatacept for the treatment of psoriatic arthritis","volume":"14","author":"Lubrano","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2021.107612_b0165","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/acr.22052","article-title":"Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjogren's syndrome: a pilot study","volume":"65","author":"Adler","year":"2013","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"7","key":"10.1016\/j.intimp.2021.107612_b0170","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2021.107612_b0175","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3109\/14397595.2016.1158773","article-title":"Effectiveness of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy) trial","volume":"26","author":"Tsuboi","year":"2016","journal-title":"Mod. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0180","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/14397595.2017.1349234","article-title":"Diffusion-weighted magnetic resonance imaging of parotid glands before and after abatacept therapy in patients with Sj\u00f6gren's syndrome associated with rheumatoid arthritis: utility to evaluate and predict response to treatment","volume":"28","author":"Takahashi","year":"2018","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0185","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10067-019-04724-w","article-title":"Effectiveness and safety of abatacept for the treatment of patients with primary Sjogren's syndrome","volume":"39","author":"Machado","year":"2020","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107612_b0190","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.chest.2017.12.010","article-title":"Sjogren syndrome with associated lymphocytic interstitial pneumonia successfully treated with tacrolimus and abatacept as an alternative to rituximab","volume":"153","author":"Thompson","year":"2018","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.intimp.2021.107612_b0195","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1177\/0961203318783057","article-title":"Combination of rituximab and abatacept as an exit strategy for repetitive B-cell depletion in children with severe autoimmune diseases: a report of three cases","volume":"27","author":"Speth","year":"2018","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0200","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0205","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tjarnlund","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2021.107612_b0210","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","article-title":"Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis","volume":"160","author":"Arabshahi","year":"2012","journal-title":"J. Pediatrics"},{"issue":"10","key":"10.1016\/j.intimp.2021.107612_b0215","first-page":"1866","article-title":"The successful use of subcutaneous abatacept in refractory anti- human transcriptional intermediary factor 1-gamma dermatomyositis skin and oesphagopharyngeal disease","volume":"57","author":"Rodziewicz","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.intimp.2021.107612_b0220","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A Randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2021.107612_b0225","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0230","article-title":"Short-term efficacy of abatacept in the treatment of refractory ocular and cutaneous Behcet's disease","volume":"1","author":"Maciel","year":"2017","journal-title":"Rheumatol. Adv. Pract."},{"issue":"4","key":"10.1016\/j.intimp.2021.107612_b0235","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/03009742.2013.812238","article-title":"Abatacept induces clinical improvement in patients with severe systemic sclerosis","volume":"43","author":"de Paoli","year":"2014","journal-title":"Scand. J. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2021.107612_b0240","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.107612_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2019.12.004","article-title":"Safety and effectiveness of abatacept in systemic sclerosis: the EUSTAR experience","author":"Castellv\u00ed","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0250","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0669-3","article-title":"Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis","volume":"17","author":"Chakravarty","year":"2015","journal-title":"Arthritis Res. Therapy"},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0255","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2021.107612_b0260","first-page":"937","article-title":"Biologics in relapsing polychondritis: a case series","volume":"31","author":"Moulis","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107612_b0265","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/rheumatology\/kep436","article-title":"Abatacept for relapsing polychondritis","volume":"49","author":"Moulis","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.intimp.2021.107612_b0270","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/annrheumdis-2013-203319","article-title":"Abatacept in relapsing polychondritis","volume":"72","author":"Peng","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2021.107612_b0275","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1136\/annrheumdis-2016-209368","article-title":"Efficacy of abatacept for IgG4-related disease over 8 months","volume":"75","author":"Yamamoto","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0280","first-page":"265","article-title":"Efficacy of abatacept in a refractory case of adult-onset Still's disease","volume":"28","author":"Quartuccio","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2021.107612_b0285","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/RHU.0b013e31822c53ad","article-title":"Refractory adult-onset still disease successfully treated with abatacept","volume":"17","author":"Ostrowski","year":"2011","journal-title":"J. Clin. Rheumatol.: Pract. Rep. Rheumatic Musculoskeletal Dis."},{"issue":"6","key":"10.1016\/j.intimp.2021.107612_b0290","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.semarthrit.2016.08.018","article-title":"Early- and late-stage morphea subtypes with deep tissue involvement is treatable with Abatacept (Orencia)","volume":"46","author":"Adeeb","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.intimp.2021.107612_b0295","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2340\/00015555-1136","article-title":"Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases","volume":"91","author":"Stausbol-Gron","year":"2011","journal-title":"Acta Derm. Venereol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107612_b0300","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.semarthrit.2020.03.020","article-title":"Abatacept in the treatment of localized scleroderma: a pediatric case series and systematic literature review","volume":"50","author":"Kalampokis","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.intimp.2021.107612_b0305","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sjogren's syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0310","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/14712598.2017.1235698","article-title":"Present and future of biologic drugs in primary Sjogren's syndrome","volume":"17","author":"Sambataro","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0315","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/annrheumdis-2019-215533","article-title":"Germline genetic patterns underlying familial rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren's syndrome highlight T cell-initiated autoimmunity","volume":"79","author":"Wang","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0320","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/sji.12079","article-title":"The important role of T cells and receptor expression in Sjogren's syndrome","volume":"78","author":"Karabiyik","year":"2013","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2021.107612_b0325","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-med-043015-123313","article-title":"Mechanisms and new strategies for primary Sjogren's syndrome","volume":"68","author":"Mavragani","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.intimp.2021.107612_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102364","article-title":"Sjogren's syndrome: old and new therapeutic targets","volume":"110","author":"Mavragani","year":"2020","journal-title":"J. Autoimmun."},{"issue":"9","key":"10.1016\/j.intimp.2021.107612_b0335","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/art.40165","article-title":"Attenuation of follicular helper T cell-dependent B cell hyperactivity by abatacept treatment in primary Sjogren's syndrome","volume":"69","author":"Verstappen","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2021.107612_b0340","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm.2752","article-title":"Taming lupus-a new understanding of pathogenesis is leading to clinical advances","volume":"18","author":"Liu","year":"2012","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.intimp.2021.107612_b0345","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.intimp.2021.107612_b0350","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.4049\/jimmunol.1500940","article-title":"Cutting edge: CTLA-4Ig inhibits memory B cell responses and promotes allograft survival in sensitized recipients","volume":"195","author":"Chen","year":"2015","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"8","key":"10.1016\/j.intimp.2021.107612_b0355","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/TP.0000000000001253","article-title":"Tracing donor-MHC class II reactive B cells in mouse cardiac transplantation: delayed CTLA4-Ig treatment prevents memory alloreactive B-cell generation","volume":"100","author":"Yang","year":"2016","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0360","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3899\/jrheum.190678","article-title":"The soluble isoform of CTLA-4 correlates with interferon-\u03b1 activity in systemic lupus erythematosus","volume":"47","author":"Dahal","year":"2020","journal-title":"J. Rheumatol."},{"issue":"13","key":"10.1016\/j.intimp.2021.107612_b0365","first-page":"1263","article-title":"Abatacept in B7-1-positive proteinuric kidney disease","volume":"370","author":"Greka","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.intimp.2021.107612_b0370","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O'Callaghan","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0375","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/clim.1999.4743","article-title":"Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells","volume":"92","author":"Nagaraju","year":"1999","journal-title":"Clin. Immunol. (Orlando, Fla.)"},{"issue":"7","key":"10.1016\/j.intimp.2021.107612_b0380","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.4049\/jimmunol.0803688","article-title":"T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells","volume":"183","author":"Fasth","year":"2009","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0385","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0002-9440(10)65141-3","article-title":"Expression of the costimulatory molecule BB-1, the Ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies","volume":"155","author":"Murata","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.intimp.2021.107612_b0390","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jaut.2013.06.006","article-title":"Treg and CTLA-4: two intertwining pathways to immune tolerance","volume":"45","author":"Walker","year":"2013","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0395","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.transproceed.2012.07.161","article-title":"Immune tolerance of skin allograft transplantation induced by immature dendritic cells of a third party carrying donor antigens in mice","volume":"45","author":"Xin","year":"2013","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.intimp.2021.107612_b0400","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19827222","article-title":"Current advances in the treatment of giant cell arteritis: the role of biologics","volume":"11","author":"Low","year":"2019","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2021.107612_b0405","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/art.40105","article-title":"Abatacept as adjunctive therapy for the treatment of giant cell arteritis: comment on the article Langford et al.","volume":"69","author":"de Boysson","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0410","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/14712598.2019.1556256","article-title":"The role of biologics in the treatment of giant cell arteritis","volume":"19","author":"Gonz\u00e1lez-Gay","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0415","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.40375","article-title":"Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides","volume":"70","author":"Sunderk\u00f6tter","year":"2018","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"},{"issue":"2","key":"10.1016\/j.intimp.2021.107612_b0420","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","article-title":"Behcet syndrome: a contemporary view","volume":"14","author":"Yazici","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"issue":"9","key":"10.1016\/j.intimp.2021.107612_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102613","article-title":"The role of IL-18 in Behcet's disease; a potential therapeutic target","volume":"19","author":"Prasinou","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2021.107612_b0430","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.imlet.2018.10.012","article-title":"Determination of mir-155 and mir-146a expression rates and its association with expression level of TNF-alpha and CTLA4 genes in patients with Behcet's disease","volume":"204","author":"Kolahi","year":"2018","journal-title":"Immunol. Lett."},{"issue":"4","key":"10.1016\/j.intimp.2021.107612_b0435","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.cell.2016.04.056","article-title":"MiR-150 controls B Cell differentiation by targeting the transcription factor c-Myb","volume":"165","author":"Xiao","year":"2016","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.intimp.2021.107612_b0440","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/ni.1798","article-title":"MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis","volume":"10","author":"Du","year":"2009","journal-title":"Nat. Immunol."},{"issue":"10103","key":"10.1016\/j.intimp.2021.107612_b0445","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0450","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13075-018-1652-6","article-title":"Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay","volume":"20","author":"Cutolo","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2021.107612_b0455","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.3389\/fimmu.2018.02998","article-title":"Targeting costimulatory pathways in systemic sclerosis","volume":"9","author":"Boleto","year":"2018","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2021.107612_b0460","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1136\/annrheumdis-2015-208213","article-title":"Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis","volume":"75","author":"Ponsoye","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0465","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1694-9","article-title":"T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis","volume":"20","author":"Boleto","year":"2018","journal-title":"Arthritis Res. Therapy"},{"issue":"5","key":"10.1016\/j.intimp.2021.107612_b0470","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MCP.0000000000000303","article-title":"T-cell immunology in sarcoidosis: Disruption of a delicate balance between helper and regulatory T-cells","volume":"22","author":"Broos","year":"2016","journal-title":"Curr. Opin. Pulmonary Med."},{"key":"10.1016\/j.intimp.2021.107612_b0475","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaut.2017.12.012","article-title":"Th17-lineage cells in pulmonary sarcoidosis and Lofgren's syndrome: friend or foe?","volume":"87","author":"Miedema","year":"2018","journal-title":"J. Autoimmun."},{"issue":"6","key":"10.1016\/j.intimp.2021.107612_b0480","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201503-0635LE","article-title":"Decreased cytotoxic T-lymphocyte antigen 4 expression on regulatory T cells and Th17 cells in sarcoidosis: double trouble?","volume":"192","author":"Broos","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"10.1016\/j.intimp.2021.107612_b0485","first-page":"1172","article-title":"Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study","volume":"77","author":"Moulis","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.107612_b0490","article-title":"Development of morphea in patients on biologic therapies: a systematic review","author":"Maliyar","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2021.107612_b0495","doi-asserted-by":"crossref","DOI":"10.1002\/art.41270","article-title":"Defining clinical subgroups in relapsing polychondritis: a prospective observational cohort study","author":"Ferrada","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"9976","key":"10.1016\/j.intimp.2021.107612_b0500","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.intimp.2021.107612_b0505","article-title":"Adult onset Still's disease: rare but important cause of raised ferritin","volume":"351","author":"Leckie","year":"2015","journal-title":"BMJ (Clinical Research ed.)"},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0510","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/acr.20319","article-title":"Tocilizumab in refractory adult Still's disease","volume":"63","author":"Pu\u00e9chal","year":"2011","journal-title":"Arthritis Care Res."},{"issue":"5","key":"10.1016\/j.intimp.2021.107612_b0515","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/s10165-008-0104-6","article-title":"Adult-onset Still's disease: a report of 28 cases and review of the literature","volume":"18","author":"Mehrpoor","year":"2008","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.intimp.2021.107612_b0520","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study","volume":"364","author":"Gottenberg","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.intimp.2021.107612_b0525","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.semarthrit.2018.03.012","article-title":"No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: a multi-database cohort study","volume":"48","author":"Kim","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0530","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-019-1992-x","article-title":"Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study","volume":"21","author":"Simon","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"8","key":"10.1016\/j.intimp.2021.107612_b0535","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3899\/jrheum.170344","article-title":"Longterm safety and efficacy of subcutaneous abatacept in patients with rheumatoid arthritis: 5-year results from a phase IIIb trial","volume":"45","author":"Genovese","year":"2018","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107612_b0540","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/acr.23824","article-title":"Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study","volume":"72","author":"Chen","year":"2020","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"3","key":"10.1016\/j.intimp.2021.107612_b0545","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.semarthrit.2019.03.007","article-title":"Comparative safety of abatacept in rheumatoid arthritis with COPD: a real-world population-based observational study","volume":"49","author":"Suissa","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.intimp.2021.107612_b0550","unstructured":"E.M. Agency, Orencia (abatacept): EU summary of product characteristics. 2016, http:\/\/www.ema.europa.eu."},{"issue":"9","key":"10.1016\/j.intimp.2021.107612_b0555","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s10067-014-2711-2","article-title":"Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies","volume":"33","author":"Hirabara","year":"2014","journal-title":"Clin. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2021.107612_b0560","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1136\/ard.2010.140129","article-title":"Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry","volume":"70","author":"Leffers","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2021.107612_b0565","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s10067-019-04508-2","article-title":"Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis","volume":"38","author":"Elmedany","year":"2019","journal-title":"Clin. Rheumatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921002484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921002484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T18:54:09Z","timestamp":1727290449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921002484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":113,"alternative-id":["S1567576921002484"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107612","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review on applications of abatacept in systemic rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107612"}}